)
Rapport Therapeutics (RAPP) investor relations material
Rapport Therapeutics Jefferies Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Pipeline and strategic positioning
RAP-219 achieved proof of concept in focal onset seizures in 2025 and bipolar mania in 2026; ~$814M in cash is expected to fund development through 2029.
FOCUS 1 and FOCUS 2 Phase III trials are enrolling; a Phase III program in primary generalized tonic-clonic seizures is planned for H1 2027.
RAP-219 bipolar mania Phase III is planned for H2 2027, following a Q1 2027 FDA End-of-Phase II meeting; two parallel studies are planned.
RAP-641, an α6β4 nicotinic program for migraine and neuropathic pain, is targeted to enter Phase I in 2027, with results expected in H2 2027.
Focal onset seizures
Phase II enrolled refractory focal onset seizure patients with RNS devices, enabling continuous EEG assessment alongside clinical seizure tracking.
RAP-219 reduced electrographic seizures by ~71% and clinical seizures by 78%; 24% of patients achieved seizure freedom.
Treatment was well tolerated; the most common adverse events were mild to moderate dizziness, headache and fatigue.
Phase III studies are powered conservatively, consistent with recent programs targeting a 30%–35% placebo-adjusted reduction in seizure frequency.
Bipolar mania
In a 21-day, placebo-controlled Phase II trial of 253 patients, RAP-219 showed a 3.1-point placebo-adjusted YMRS difference at week 3 and a 15.4-point absolute change in the treatment arm.
All 11 YMRS items improved; four were statistically significant. The secondary CGI scale showed a significant 0.4-point treatment difference versus placebo.
Adverse events were mild to moderate; AE-related withdrawal was 3.2% with RAP-219 versus 0.8% with placebo, while overall treatment discontinuations were not driven by AEs.
Phase III design may use 1.25 mg versus 0.75 mg in Phase II to achieve higher receptor occupancy earlier; global sites are under consideration to manage placebo response.
Phase III planning discussed three studies to secure at least two positive results; the design discussion cited 90% power, α=0.05 and a YMRS difference in the four-point range.
- RAP-219 advances across epilepsy and bipolar, backed by cash through end-2029.RAPP
Stifel 2026 Healthcare Conference 2026 - Phase 2 mania success and $815.4M estimated liquidity support 2027 pipeline plans.RAPP
Q3 2026 - RAP-219 met both Phase 2 mania endpoints; two Phase 3 trials are planned for H2 2027.RAPP
Study result - RAP-219 targets bipolar mania's unmet needs with a novel mechanism and rigorous clinical trials.RAPP
KOL event - RAP-219 targets major neuropsychiatric markets with novel mechanisms and pivotal trial readiness.RAPP
TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit - RAP-219 advances in bipolar mania and seizures, with a transformative long-acting injectable in development.RAPP
12th Annual Cantor Fitzgerald Global Healthcare Conference - RAP-219 shows robust efficacy in drug-resistant epilepsy, advancing to Phase 3 with strong financial backing.RAPP
Corporate presentation - Net loss widened to $76.5M despite $20M in new licensing revenue; cash runway extends into 2029.RAPP
Q2 2026 - RAP-219 delivers robust efficacy in drug-resistant epilepsy, advancing toward major market opportunities.RAPP
Corporate presentation
)
)
)
)
)
)
)
)